ApoPharma - DRIVING INNOVATION

   >  Treat  >  Deferoxamine Mesylate, Injection®

Deferoxamine Mesylate

Injection 500 mg
Injection 2 g

ApoPharma now markets a generic version of Desferal® in single-dose vials containing 500 mg and 2 g of sterile, lyophilized deferoxamine mesylate.

Deferoxamine mesylate is an iron-chelating agent indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. It is provided in vials for intramuscular, subcutaneous, and intravenous administration. The introduction of deferoxamine mesylate for injection to the ApoPharma USA Portfolio in addition to its product Ferriprox® (deferiprone) reflects our long-standing commitment to patients suffering from iron overload.

Click here to view the Product Insert for the 500 mg and 2 g injection of Deferoxamine Mesylate.

500x500